Back to News
Market Impact: 0.45

ACN Factor-Based Stock Analysis

ACNNDAQ
Company FundamentalsAnalyst InsightsTechnology & Innovation
ACN Factor-Based Stock Analysis

According to Validea's guru fundamental report, Accenture PLC (ACN) receives an 86% rating based on their Patient Investor model, which is based on Warren Buffett's published investment strategy. The strategy favors firms with predictable profitability, low debt, and reasonable valuations, all of which ACN appears to meet based on underlying fundamentals; a score above 80% typically indicates interest in the stock, while a score above 90% indicates strong interest.

Analysis

Accenture PLC (ACN) has received a notable 86% rating from Validea's Patient Investor model, a framework derived from Warren Buffett's investment principles which prioritize companies demonstrating long-term, predictable profitability, low leverage, and attractive valuations. As a large-cap growth stock within the Computer Services industry, ACN's 86% score signifies a level of interest from this strategy, as scores above 80% typically indicate such interest, while those exceeding 90% suggest strong conviction. Critically, ACN has passed all nine fundamental tests applied by this specific strategy: Earnings Predictability, Debt Service, Return on Equity, Return on Total Capital, Free Cash Flow, Use of Retained Earnings, Share Repurchase, Initial Rate of Return, and Expected Return. This comprehensive positive assessment aligns with the strongly positive sentiment (0.85 specific to ACN, overall sentiment 0.75) indicated by associated data signals, underscoring robust underlying fundamentals as perceived through this value-oriented investment lens.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

strongly positive

Sentiment Score

0.75

Ticker Sentiment

ACN0.85
NDAQ0.00

Key Decisions for Investors

  • Given Accenture's strong alignment with Buffett-style investment criteria and its comprehensive passing of key fundamental tests, investors seeking exposure to a large-cap growth stock with demonstrated profitability and prudent capital management should consider ACN for further due diligence.
  • The 86% rating, while indicative of positive fundamentals and interest from the Patient Investor model, falls short of the 'strong interest' threshold (above 90%), suggesting investors should monitor ACN's continued performance against these criteria.
  • Investors whose strategies emphasize long-term value, predictable earnings, and financial strength may find ACN particularly aligns with their objectives, reflecting the core tenets of the Validea model highlighted.